News Breaks |
|
|
| January 11, 2013 |
| 06:02 EDT |  | CELG, KORS | Stocks with implied volatility movement; CELG KORS
Stocks with implied volatility movement; Celgene (CELG), Michael Kors (KORS) according to iVolatility. |
|
|
News For CELG;KORS From The Last 14 Days Check below for free stories on CELG;KORS the last two weeks. |
|
|
| June 17, 2013 |
| 05:44 EDT |  | CELG | Celgene awarded marketing authorisation for Revlimid from EC
 Subscribe for More Information |
|
| June 14, 2013 |
| 08:23 EDT |  | CELG | Celgene multiple likely to expand further, says Cantor
Cantor believes that Celgene is in the process of diversifying its revenue as it introduces new products. The firm has an upbeat outlook on the company's Apremilast drug and keeps a Buy rating on the stock. |
|
| 06:07 EDT | | CELG | Celgene achieves statistical significance for endpoints in Behcet trial
Subscribe for More Information |
|
| June 13, 2013 |
| 14:59 EDT | | KORS | Michael Kors options active on conjecture of weak May data
Michael Kors June 65 weekly calls and July 55 puts are active on total call volume of 9K calls (9K puts) on conjecture of weak May data. June weekly call option implied volatility is at 70, June is at 41, July is at 41, August and November is at 40; compared to its 26-week average of 43 according to Track Data. Active option volume suggests traders taking positions for price movement. |
|
| 14:50 EDT |  | KORS | Rumor: Michael Kors down on conjecture of weak May data
|
|
| 10:15 EDT |  | CELG | Celgene management to meet with Jefferies
Subscribe for More Information |
|
| 10:14 EDT | | CELG | Celgene management to meet with Guggenheim
Subscribe for More Information |
|
| 10:05 EDT |  | CELG | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 08:03 EDT | | CELG | Celgene should continue to be bought, says RW Baird
Baird continues to be buyers of Celgene citing its new $3B share repurchase program and the publication of new trial data for apremilast's PALACE-1 efficacy. Shares are Outperform rated with a $130 price target. |
|
| 07:33 EDT | | CELG | Celgene upgraded to Buy from Hold at Argus
Subscribe for More Information |
| |
| 05:24 EDT | | CELG | Celgene presents data from PALACE 3 study
Celgene International Sŕrl, a wholly-owned subsidiary of Celgene, announced results from PALACE 3, the company’s third phase III study in psoriatic arthritis, or PsA, at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain. The PALACE 3 study, which evaluated 495 patients, demonstrated statistical significance in achieving the primary endpoint of American College of Rheumatology 20 score at week 16 for patients receiving apremilast compared to placebo. PALACE 3 is the third pivotal phase III, randomized, placebo-controlled study evaluating Celgene’s novel, oral small-molecule inhibitor of phophodiesterase 4 in patients with active psoriatic arthritis who had previously received and/or failed an oral disease-modifying anti-rheumatic drug, or DMARD, and/or biologic therapy. In this study, apremilast treatment was used alone or in combination with oral DMARDs. By design, PALACE 3 includes a subset of 270 patients with significant active psoriatic skin involvement. Patients in the 30 mg BID active treatment arm also demonstrated significant and sustained improvements in psoriasis-related endpoints, including Psoriasis Area Severity Index, or PASI, 50 and PASI-75 at week 24. Similar improvements in 30 mg BID-treated patients were also observed in key secondary endpoints, including various measures of physical function, signs and symptoms and quality of life. The safety and tolerability profile of apremilast in PALACE 3 was consistent with other previously reported phase III studies of the therapy in psoriatic arthritis. |
|
| June 12, 2013 |
| 08:01 EDT | | CELG | Celgene announces additional $3B share repurchase program
Celgene announced that its Board of Directors authorized the repurchase of up to an additional $3.0B of the company’s common stock. Year-to-date, Celgene has repurchased approximately $1.8B of its common stock and has exhausted the previous $2.5B stock repurchase authorization. |
|
| 08:00 EDT | | CELG | Celgene announces additional $3B share repurchase program
Subscribe for More Information |
|
| 07:38 EDT | | CELG | Celgene reports positive Phase III results from psoriatic arhrititis candidate
Subscribe for More Information |
|
| 07:22 EDT | | KORS | Piper Jaffray to host a conference
Subscribe for More Information |
|
| June 10, 2013 |
| 07:40 EDT | | CELG | Leerink's biotech analyst holds analyst/industry conference call on ASCO
Subscribe for More Information |
|
| June 7, 2013 |
| 09:33 EDT | | CELG | Celgene management to meet with Lazard Capital
Meeting to be held in Zurich on June 14 hosted by Lazard Capital. |
|
| June 6, 2013 |
| 06:19 EDT | | CELG | Celgene implied volatility at upper end of index mean range
|
|
| June 5, 2013 |
| 13:02 EDT | | CELG | FDA approves Celgene's supplemental new drug application for Revlimid
Subscribe for More Information |
|
| 07:48 EDT | | CELG | FDA PDUFA Date for Celgene's Revlimid scheduled for June 5, 2013
Subscribe for More Information |
| |
|
|
|
|
